A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., autoimmunity) can cause permanent hair loss, a new study shows. This regimen ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says. The antibiotic ...

A new study reveals that low-dose antibiotics can effectively treat lymphocytic scarring alopecia, a rare hair loss condition ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says.The antibi ...

Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.